undamentalytics Newsletter

Douglas Richard: insider trades

Director at 3 companies we cover. 16 open-market purchases and no sales not made under a pre-set plan, reported from June 21, 2011 to March 20, 2026.

Would copying Douglas Richard’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 5 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on February 22, 2017 into $15,677 by November 2, 2026, +4.8% a year. The copy held shares only 31% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $14,160, +3.7% a year (the S&P 500 held throughout made $37,271, +14.6% a year). Beta against the index was 0.86. Twelve months after each report, the average purchase was +6.3% against the S&P 500 (median +5.7%), and 80% beat it. Measured from the trade date, the insider’s own timing, the average was +1.8%.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$20.0k$40.0k 20172019202120232025 $37.3k$15.7k$14.2k
Copying Douglas RichardS&P 500, same days investedS&P 500, held throughout $10,000 copying Douglas Richard’s open-market purchases from February 22, 2017, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
+4.8%
S&P 500, same days invested
+3.7% (held throughout +14.6%)
Time in shares
31%
Sharpe ratio (S&P 500)
0.30 (0.70)
Biggest drop (S&P 500)
−80% (−34%)
Market sensitivity (beta)
0.86
Purchases copied
5

Trade by trade

Douglas Richard: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 5 −15.8% −13.2% 0% 3 — — Not enough years
Purchases, 6 months after the report 5 −40.5% −43.9% 0% 3 — — Not enough years
Purchases, 12 months after the report 5 +6.3% +5.7% 80% 3 — — Not enough years
Purchases, 12 months after the trade 4 +1.8% +7.5% 75% 3 — — Not enough years
Sales, 3 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the report 0 — — — — — — Not enough years
Sales, 12 months after the trade 0 — — — — — — Not enough years

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Novavax Inc NVAX —70June 21, 2011May 12, 2017
Aldeyra Therapeutics, Inc. ALDX —60February 21, 2017March 20, 2026
Maxcyte, Inc. MXCT —30November 23, 2021August 13, 2025

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
March 20, 2026March 19, 2026 ALDX Purchase $98,000 not yetnot yetnot yet
August 13, 2025August 13, 2025 MXCT Purchase $111,200 not yetnot yetnot yet
March 30, 2023March 29, 2023 MXCT Purchase $345,600 not yetnot yetnot yet
November 23, 2021November 22, 2021 MXCT Purchase $222,400 −24.7%−20.3%−29.2%
March 17, 2020March 16, 2020 ALDX Purchase $110,000 not yetnot yetnot yet
September 17, 2019September 13, 2019 ALDX Purchase $30,000 −12.9%+9.9%+10.5%
September 13, 2019September 11, 2019 ALDX Purchase $117,800 −18.4%+4.1%+4.5%
September 11, 2019September 9, 2019 ALDX Purchase $100,000 −13.2%+5.7%not yet
May 12, 2017May 11, 2017 NVAX Purchase $186,000 not yetnot yetnot yet
February 21, 2017February 17, 2017 ALDX Purchase $180,000 −10.0%+32.3%+21.5%
September 22, 2016September 21, 2016 NVAX Purchase $172,000 not yetnot yetnot yet
March 25, 2014March 25, 2014 NVAX Purchase $216,500 not yetnot yetnot yet
June 13, 2013June 12, 2013 NVAX Purchase $95,000 not yetnot yetnot yet
April 11, 2012April 10, 2012 NVAX Purchase $60,500 not yetnot yetnot yet
August 11, 2011August 9, 2011 NVAX Purchase $60,000 not yetnot yetnot yet
June 21, 2011June 20, 2011 NVAX Purchase $102,000 not yetnot yetnot yet

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Douglas Richard traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.